医学
肠易激综合征
膨胀
血管活性肠肽
内科学
鸦片剂
腹痛
胃肠病学
胃排空
胃肠道
胃泌素
兴奋剂
内脏痛
胃肠功能
内分泌学
药理学
受体
神经肽
伤害
胃
分泌物
作者
M Delvaux,David Wingate
标识
DOI:10.1177/030006059702500501
摘要
The actions of trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral μ, k and δ opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. Recently, trimebutine has also been shown to decrease reflexes induced by distension of the gut lumen in animals and it may therefore modulate visceral sensitivity. Clinically, trimebutine has proved to be effective in the treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome, at doses ranging from 300 to 600 mg/day. It is also effective in children presenting with abdominal pain.
科研通智能强力驱动
Strongly Powered by AbleSci AI